CME Information

MS in the Crossfire 2014: Where Are We Now?

This program has expired and is no longer available for credit.

Learning Objectives
At the conclusion of this continuing education activity, participants should be able to:

  • Discuss the potential benefit of early aggressive therapy for relapsing-remitting MS (RRMS)
  • Describe new agents and dosing options for management of RRMS
  • Explain the correlation of MRI to progressing disease
  • Describe current approaches to managing RRMS

Activity Goal
This activity is designed to address the following ABMS / IOM competencies:
Patient Care and Medical Knowledge

Designation Statement
Ciné-Med designates this enduring material for a maximum of 2 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

How to get CME credit
To receive credit, participants must view the webcast, register on this site, and successfully complete the post-test and evaluation (successful passing grade >70%). Certificates can be printed on line.
Time to Complete Activity for each section:
1 hour

Target Audience
This activity is intended for neurologists and other medical professionals with a specific interest in the management of Multiple Sclerosis.

Release Date: November 7, 2014
Expiration Date: November 7, 2015

Accreditation
This activity has been planned and implemented by Ciné-Med and Peer Health Communications. Ciné-Med is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing medical education for the health care team.

Disclosure statement
Ciné-Med, Inc., in accordance with the ACCME’s Standards for Commercial Support, requires individuals with control over content to disclose to learners any relevant financial relationships(s). Faculty disclosures can be found on the Faculty page.

This activity is supported by an educational grant from Teva CNS.